Ovarian, Glioblastoma & Non-Small Cell Lung Cancer: Jefferson Researchers Present at AACR

Several researchers from Jefferson’s Kimmel Cancer Center presented abstracts at the American Association for Cancer Research Annual Meeting 2012 in Chicago. Some of those findings include:

HuR and Ovarian Cancer

Silencing HuR may be a promising therapeutic approach for the treatment of ovarian cancer, according to an abstract presented at AACR by researchers from Thomas Jefferson University, Lankenau Institute for Medical Research, the Geisinger Clinic and the Massachusetts Institute of Technology.

HuR is a RNA-binding protein that post-transcriptionally regulates genes involved in the normal cellular response to cancer-associated stressors, like DNA damage, nutrient depletion and therapeutic agents.  When triggered by stress, HuR translocates from the nucleus to the cytoplasm where it potently influences translation of key tumor promoting mRNAs by mRNA stabilization and direct facilitation of translation.

Previously, it has been shown that HuR expression is a prognostic marker in ovarian cancers. Thus, researchers tested the effects of manipulating HuR expression levels on ovarian tumor growth characteristics and tested the hypothesis that silencing HuR through delivery of an HuR siRNA would be effective in suppressing the growth of ovarian tumors.

Following treatment of ovarian cancer cells in culture with an adenovirus containing the HuR coding sequence, HuR expression was increased by about 40% above control cells.

In the patient cohort, researchers also detected HuR activation (i.e., cytoplasmic HuR positivity) in twenty-four of thirty four patients (71 percent), providing evidence that the majority of patients have activated HuR.

“These data provide evidence that silencing HuR, even as a monotherapeutic strategy, may be a promising therapeutic approach for the treatment of ovarian cancer,” wrote the authors.

Authors of the paper include Janet A. Sawicki and Yu-Hung Huang, of Lankenau Institute for Medical Research, Charles J. Yeo, Agnieszka K. Witkiewicz, Jonathan R. Brody, of Thomas Jefferson University, Radhika P. Gogoi, of Geisinger Clinic, Danville, Pa., and Kevin Love and Daniel G. Anderson, of Massachusetts Institute of Technology, Cambridge, Mass.

This work was supported by the Marsha Rivkin Center for Ovarian Cancer Research.

Radiotherapy and Glioblastoma

Radiotherapy’s effect on glioblastoma (GBM) is enhanced in the presence of a heat shock protein and a P13K inhibitor, researchers from the Department of Radiation Oncology reported at AACR.

Glioblastoma tumors frequently contain mutations in the tumor suppressor gene, PTEN, leading to loss of PTEN activity, which causes overactivation of the PI3K pathway, inducing inhibition of apoptosis and radioresistance.

Heat-shock protein 90 (HSP90) is a molecular chaperone that is over-expressed in GBM and that has among its client proteins, PI3K and Akt.

It was hypothesized that dual inhibition of HSP90 and PI3K signaling would additively or synergistically radiosensitize GBM through inhibition of radiation-induced PI3K/Akt signaling, leading to enhanced apoptosis.

Confirming their theory, the researchers found that the response of glioblastoma to radiotherapy was enhanced in the presence of BKM120 and HSP990. Enhanced apoptosis also contributed to the mechanism of cell death.

Authors of the study include Phyllis Rachelle Wachsberger, Yi Liu, Barbara Andersen, and Adam P. Dicker, of the Department of Radiation Oncology at Thomas Jefferson University Hospital and Richard Y. Lawrence, of Jefferson and the Sheba Medical Center, Tel Hashomer, Israel.

This work was supported by a grant from Novartis Pharmaceuticals.

Non-Small Lung Cancer and DACH1

Researchers from the Kimmel Cancer Center at Jefferson have identified a protein relationship that may be an ideal treatment target for non-small cell lung cancer (NSCLC).  They presented their findings at AACR.

DACH1, a cell fate determination factor protein, appears to be a binding partner to p53, a known tumor suppressor, which inhibits NSCLC cellular proliferation.

As cancer develops and becomes more invasive, the expression of DACH1 decreases. Clinical studies have demonstrated a reduced expression of the DACH1 in breast, prostate and endometrial cancer.

In a previous study of more than 2,000 breast cancer patients, Jefferson researchers found that a lack of DACH1 expression was associated with a poor prognosis in breast cancer patients. Patients who did express DACH1 lived an average of 40 months longer.

Genetic studies have identified several oncogenes activated in lung cancer, including K-Ras and EGFR. Given the importance of the EGFR in human lung cancer, researchers examined the role of DACH1 in lung cancer cellular growth, migration and DNA damage response.

For this study, endogenous DACH1 was reduced in human NSCLC, with expression levels of DACH1 correlating inversely with clinical stage and pathological grade.

Re-expression of DACH1 also  reduced lung cancer cell colony formation and cellular migration. Cell cycle analyses demonstrated that G2/M block by ectopic expression of DACH1 occurs synergistically with p53.

Fluorescent microscopy demonstrated co-localization of DACH1 with p53, and immunoprecipitation and western blot assay showed DACH1 association with p53.

“DACH1 enhanced the cytotoxcity of cisplatin and doxorubicin, two commonly used drugs for NSCLC,” the authors write in the abstract. “Together, our studies demonstrate that p53 is a DACH1 binding partner that inhibits NSCLC cellular proliferation.”

Authors of the study include Ke Chen, Kongming Wu, Wei Zhang, Jie Zhou, Timothy Stanek, Zhiping Li, Chenguang Wang, L. Andrew Shirley, Hallgeir Rui, Steven McMahon, Richard G. Pestell, of  Thomas Jefferson University, Kimmel Cancer Center and Huazhong University of Science and Technology, Wuhan, China.



AACR: New Biomarker to Identify Hepatitis B-Infected Patients at Risk for Liver Cancer

CHICAGO— Hepatitis B-infected patients with significantly longer telomeres—the caps on the end of chromosomes that protect our genetic data— were found to have an increased risk of getting liver cancer compared to those with shorter ones, according to findings presented by researchers at Jefferson’s Kimmel Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2012.

The relative telomere length in hepatitis B-infected cases with liver cancer was about 50 percent longer than the telomere length of the cancer-free hepatitis B-infected controls.

A strong correlation between telomere length and non-cirrhotic hepatocellular carcinoma (HCC), a liver cancer commonly caused from hepatitis B and C viral infections, could help physicians better stratify the hepatitis B population in an effort to better prevent and treat the disease.

Previous reports have suggested telomere length plays a role in cancer prediction; however, there have been conflicting results and the majority of the studies measured telomere length in liver cells (hepatocytes) and white blood cells.

Here, Hushan Yang, Ph.D., of the Division of Population Science at the Department of Medical Oncology at Thomas Jefferson University and Jefferson’s Kimmel Cancer Center, and colleagues used circulating cell-free serum DNA from an existing and ongoing clinical cohort at the Liver Disease Prevention Center at Thomas Jefferson University Hospital.

Tapping into a cohort of almost 2,600 Korean Americans, a population disproportionately infected with hepatitis B, the team analyzed blood samples from over 400 hepatitis B-infected patients to compare relative telomere length using quantitative real-time polymerase chain reaction (qRT-PCR).

This nested case-control study included 140 hepatitis B-HCC cases and 280 cancer-free hepatitis B controls. Demographic and clinical data were obtained for each patient through medical chart review and consulting with treating physicians.

All participants were restricted to Korean hepatitis B patients to control the confounding effects of ethnicity and HCC etiology. The large majority of the patients were infected at birth or childhood, making this population an ideal resource to study the long-term outcome of hepatitis B infection at the population level.

The hepatitis B-HCC cases were found to have a relative telomere length about 50 percent longer than the cancer-free controls (0.31 versus 0.20, P=0.003), a statistically significant difference.

The difference, however, was also only evident in males and in non-cirrhotic patients, and not cirrhotic patients, possibly because that the effect conferred by telomere length was overshadowed by the strong association between cirrhosis and HCC. There were also no statistical differences between cohorts with respect to age and smoking status.

“This is the first study to demonstrate that relative telomere length in circulating cell-free serum DNA could potentially be used as a simple, inexpensive and non- invasive biomarker for HCC risk,” said Dr. Yang. “This sets the stage for further retrospective and prospective investigations, in-depth molecular characterizations, and other assessments to determine the clinical value of serum DNA telomere length in risk prediction and early detection of HCC.”

Co-authors of the study were Shaogui Wan, Xiaoying Fu, Ronald Myers, Ph.D., Division of Population Science, Department of Medical Oncology, Thomas Jefferson University; Hie-Won Hann, M.D., Richard Hann, Jennifer Au, M.D., Division of Hepatology and Gastroenterology, Department of Medicine, Thomas Jefferson University; and Jinliang Xing, Department of Cell Biology, Fourth Military Medical University in China.

This study was supported by two grants from the National Cancer Institute, a Tobacco Grant from the Pennsylvania Department of Health, an American Cancer Society grant, and a Research Scholar Award from the V Foundation for Cancer Research.



AACR: Eliminating the ‘Good Cholesterol’ Receptor May Fight Breast Cancer

CHICAGO— Removing a lipoprotein receptor known as SR-BI may help protect against breast cancer, as suggested by new findings presented at the American Association for Cancer Research Annual Meeting 2012 by Jefferson’s Kimmel Cancer Center researchers.

In vitro and mouse studies revealed that depletion of the SR-BI resulted in a decrease in breast cancer cell growth.

SR-BI is a receptor for high-density lipoproteins (HDL) that are commonly referred to as “good cholesterol” because they help transport cholesterol out of the arteries and back to the liver for excretion.

The team, including Christiane Danilo, of the Department Stem Cell Biology and Regenerative Medicine at Thomas Jefferson University, and Philippe G. Frank, Ph.D., an assistant professor in the Department of Stem Cell Biology and Regenerative Medicine at Jefferson, had good reason to believe that SR-BI played a role in breast cancer growth: Previous lab research had revealed that mice fed a high cholesterol diet develop more advanced tumors and their tumors produce more SR-BI.

To further investigate SR-BI’s role in breast cancer tumors, the team manipulated levels of the receptor in human breast cancer cell lines and examined its effect on tumor formation in a mouse model.

In vitro, they found that ablation of the receptor protein in breast cancer cells led to a decrease in cancer cell proliferation, migration and invasion. Mouse models also showed that depletion of the receptor could confer protection against tumor growth.

Environmental factors, such as diet and obesity, have long been considered risk factors for the high breast cancer incidence in the Western world, and epidemiologic evidence indicates that cancer patients display abnormal levels of cholesterol carrying lipoproteins. However, the role of cholesterol in breast cancer had not yet been specifically examined.

“The results of this novel study show that depletion of SR-BI reduces cancer cell and tumor growth, suggesting that it could play an important role in breast cancer,” said Dr. Frank. “More studies are warranted to further characterize the role of SR-BI in tumor progression.”

Other researchers include Michael P. Lisanti, M.D., Ph.D., Chairman of the Department of Stem Cell Biology and Regenerative Medicine at Jefferson, and Maria Antonietta Mainieri of the University of Calabria, Rende, in Italy.

The study was funded by the Susan G. Komen Foundation.



Radiation Therapy Students use Virtual Reality Training (VERT)

Students in the Radiation Therapy bachelor’s degree program in the Department of Radiologic Sciences at Jefferson School of Health Professions are now encouraged to make something they once dreaded — mistakes.

Before they embark on their clinical rotation, where one wrong move might harm a patient, they’ll slip on 3D goggles and simulate various procedures using cutting-edge virtual reality software called Virtual Environment Radiotherapy Training (VERT).

Jefferson is one of three schools in the U.S. – and the only one on the east coast – to use VERT.

The  new technology allows students to practice controlling all three linear accelerator models they’ll encounter in hospitals. Using replica control panels, they’ll position the virtual patient and deliver a targeted dose of radiation. The software allows them to see the impact of the beam (which is invisible in real life) on the patient’s internal anatomy.

Matthew Marquess, MBA, BS, RT(T), program director for radiation therapy, believes the software package is an investment in patient safety. “I’m a soul believer that making mistakes is the best education for students,” he says. “Because when they come across that situation, a red flag is going to pop up.”

Marquess says VERT increases students’ hands-on training time. “We’re hoping that by using this equipment in the classroom setting, they’ll go into the clinic with more confidence,” he says.

In addition to radiation therapists, VERT will be used to train medical dosimetrists.

Marquess also hopes to collaborate closely with the Bodine Center for Radiation Oncology and Jefferson’s Kimmel Cancer Center in the future.



Dr. Leonard Gomella, Program Director for IPCC in New York

Dr. Leonard Gomella, Program Director of 2012's IPCC

Leonard G. Gomella, M.D., FACS, Chair of Urology at Thomas Jefferson University Hospital and Director of Clinical Affairs at the Kimmel Cancer Center at Jefferson, will serve as the Program Director for the Fifth Annual Interdisciplinary Prostate Cancer Congress (IPCC) at the New York Marriott East Side in New York City on March 31.

This full-day continuing medical education (CME) activity entitled Novel Perspectives – Evolving Therapies and Advances In Standard of Care will address the differences that currently exist between urologists’, medical oncologists’, and radiation oncologists’ approaches to treating prostate cancer.

World-renowned thought leaders have been brought together to foster consensus about the best management of prostate cancer from the vantage point of interdisciplinary care teams. Topics of vital interest that will be include: hormonal therapies; imaging and staging; surgical advances; radiation therapies; and emerging multimodal therapies.

The IPCC will include interactive cases designed to highlight multidisciplinary approaches for the management of prostate cancer with the overall goal of improving patient outcomes.

Topics include  prostate-specific antigen testing in diagnosing patients with prostate cancer, and emerging bone-related therapies for treating prostate cancer.

Dr. Gomella told OncLive that the value of the conference for attendees is its focus on practical applications of these new developments. “When they go back to the patient setting, they can actually use [this information] in their daily patient care,” he said.

For more information, please visit, http://cancerlearning.onclive.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/702/index.php

http://www.onclive.com/publications/Oncology-live/2012/january-2012/IPCC-Conference-to-Focus-on-Issues-Facing-Clinicians



Jefferson Physicians Host Bilingual Health Education Session for the Annual Latinas United for the Cure

On Saturday, March 24, physicians from Jefferson’s Kimmel Cancer Center hosted a health education session entitled “The Basics and Beyond: Empowering all Latinas to Fight Breast Cancer” in both English and Spanish, as part of a free Komen Philadelphia event for the Latina community in Philadelphia and surrounding areas.

Edith Mitchell, M.D., FACP, of Jefferson’s Kimmel Cancer Center Multi-Disciplinary Breast Cancer Team, led the health session, and was also awarded the “Partner in Health Equality” award from the Komen Foundation. 

Philadelphia Councilwoman Maria-Quiñones Sánchez was among the motivational and educational speakers. The Mistress of Ceremonies was Rev. Bonnie Camarda, Director of Partnerships, Salvation Army

Opportunities at Latinas United for the Cure, held at Philadelphia Marriott Downtown, included breast health education and support through expert panels, survivor testimonials, peer interaction and take-home materials; mammogram signups for eligible women; entertainment; continental breakfast and lunch.

Dr. Edith Mitchell received the Partner in Health Equality Award

More than 1,000 Latina women celebrated victory over disease with dancing and singing, accompanied by Grupo Fuego.

The health education session from Jefferson given in English included:

  • Introduction & Overview by Pramila Rani Anne, MD; Associate Professor, Department of Radiology
  • Update on Breast Cancer Screening by Annina Wilkes, MD; Associate Professor, Breast Imaging/Ultrasound Department of Radiology
  • The Latest on Surgical Management of Breast Cancer by Adam Berger, MD; Associate Professor, Department of Surgery
  • Symptom Management During Breast Cancer Treatment by Rebecca Jaslow, MD; Assistant Professor, Department of Medical Oncology
  • Personalized Medicine – the New Paradigm by Tiffany Avery, MD; Assistant Professor, Department of Radiation Oncology

The health education session given in Spanish included:

  • Introduction & Overview by Maria Rodriguez, RN, BSN, MSN; Clinical Nurse Specialist, Department of Medical Oncology
  • Update on Breast Cancer Screening by Angelica Manzur; Medical Student IV; Research Assistant, Department of Medical Oncology
  • The Latest on Surgical Management of Breast Cancer by Jose Munoz, MD; Research Post Doctoral Fellow, Department of Surgery
  • Symptom Management During Breast Cancer Treatment by Alex Mejia, MD; Post Doctoral Fellow, Department of Oncology
  • Personalized Medicine - the New Paradigm by Ubaldo Martinez-Outschorn, MD; Assistant Professor, Department of Medical Oncology

Dr. Mitchell, who is also the Director of the Center to Eliminate Cancer Disparities at Jefferson’s Kimmel Cancer Center, was awarded the “Partner in Health Equality” award for her work in the community, including breast cancer care and health education.

With breast cancer being the leading cause of cancer death among Latina women, the event empowers multiple generations of Latinas to take the steps that can save their lives today, and establish healthy lifestyle practices that support growing power over the disease for their children.

Latinas United for the Cure is designed specifically to empower the Latina community in improving this statistics, fighting back and surviving breast cancer.

*Photos provided by LuzSelenia Loeb



Jefferson Graduate Student Receives Joanna M. Nicolay Melanoma Foundation ‘Research Scholar Award’

From left to right: Dr. Andrew Aplin of Jefferson's Department of Cancer Biology, JMNMF's Denise Safko, Awardee Kevin Basile, JMNMF President Greg Safko, and Dr. Richard Pestell, Director of the KCC

Kevin Basile, a Thomas Jefferson University graduate student in the Genetics Ph.D. Program, was one of nine students from leading cancer centers across the U.S. to receive a $10,000 “Research Scholar Award” from the Joanna M. Nicolay Melanoma Foundation (JMNMF) for his exceptional research work.

Two members of the board of directors for JMNMF, including Secretary Denise Safko and President Greg Safko, presented the award to Mr. Basile at the Kimmel Cancer Center’s Bluemle Life Sciences Building on March 26.

Mr. Basile was also accompanied by Dr. Richard Pestell, Director of the Kimmel Cancer Center, and Andrew Aplin, Ph.D., an Associate Professor in the Department of Cancer Biology.

The stop was part of a “road-show” of sorts for JMNMF committee and board members, who are traveling up the Northeast from Baltimore to Boston for RSA ceremonies.

Mr. Basile’s research focuses on resistance to RAF inhibitors in melanoma and methods to enhance the efficacy of those inhibitors.

The JMNMF is a nonprofit public charity founded in January 2004 to foster melanoma education, advocacy and research. In just eight years, the Foundation has grown dramatically to become an influential voice in the melanoma community and is now established as a national, and international, “voice for melanoma prevention, detection, care and cure.”

The nationally competitive grants increased dramatically by nearly 30 percent in 2012 (following a 40 percent funding increase in 2011) to significantly enhance the potential for advancements in the melanoma cancer field and encourage a larger number of students to choose melanoma research as their professional career path.

The 2012 RSA applicant pool and cancer research centers represented grew to include 42 of the country’s most promising young melanoma researchers, and 28 prominent National Cancer Institute (NCI)-Designated Cancer Centers or members of the Association of American Cancer Institutes (AACI).

This represents a dramatic 60 percent increase in students and 75 percent growth in research institutions participating, respectively. As first in the U.S. to fund graduate student melanoma researchers, the JMNMF program is celebrating the program’s sixth anniversary.

“Our Foundation’s ‘Research Scholar Awards’ are invaluable at the grassroots level, to specifically grow interest in melanoma research, at qualified cancer centers across the country,” said Robert E. Nicolay, JMNMF Chairman. “If we can attract the brightest minds that are considering, or are already within, the nation’s cancer research pipelines, to pursue a career in melanoma research – we’re that much closer to better understanding the disease, identifying the means for effective treatments and, most importantly, finding a cure for this deadly and very prevalent disease.”

For more information about JMNMF, please visit: http://www.melanomaresource.org/



Biomarker Links Clinical Outcome with New Model of Lethal Tumor Metabolism

Researchers at the Kimmel Cancer Center at Jefferson have demonstrated for the first time that the metabolic biomarker MCT4 directly links clinical outcomes with a new model of tumor metabolism that has patients “feeding” their cancer cells.  Their findings were published online March 15 in Cell Cycle.

To validate the prognostic value of the biomarker, a research team led by Agnieszka K. Witkiewicz, M.D., Associate Professor of Pathology, Anatomy and Cell Biology at Thomas Jefferson University, and Michael P. Lisanti, M.D., Ph.D., Professor and Chair of Stem Cell Biology and Regenerative Medicine at Jefferson, analyzed samples of patients with triple negative breast cancer, one of the most deadly of breast cancers, with fast-growing tumors that often affect younger women.

A retrospective analysis of over 180 women revealed that high levels of the biomarker MCT4, or monocarboxylate transporter 4, were strictly correlated with a loss of caveolin-1 (Cav-1), a known marker of early tumor recurrence and metastasis in several cancers, including prostate and breast.

“The whole idea is that MCT4 is a metabolic marker for a new model of tumor metabolism and that patients with this type of metabolism are feeding their cancer cells. It is lethal and resistant to current therapy,” Dr. Lisanti said. “The importance of this discovery is that MCT4, for the first time, directly links clinical outcome with tumor metabolism, allowing us to develop new more effective anti-cancer drugs.”

Analyzing the human breast cancer samples, the team found that women with high levels of stromal MCT4 and a loss of stromal Cav-1 had poorer overall survival, consistent with a higher risk for recurrence and metastasis, and treatment failure.

Applying to a Triple Threat

Today, no such markers are applied in care of triple negative breast cancer, and as a result, patients are all treated the same. Identifying patients who are at high risk of failing standard chemotherapy and poorer outcomes could help direct them sooner to clinical trials exploring new treatments, which could ultimately improve survival.

“The idea is to combine these two biomarkers, and stratify this patient population to provide better personalized cancer care,” said Dr. Witkiewicz

The findings suggest that when used in conjunction with the stromal Cav-1 biomarker, which the authors point out has been independently validated by six other groups worldwide, MCT4 can further stratify the intermediate-risk group into high and low risk.

Since MCT4 is a new druggable target, researchers also suggest that MCT4 inhibitors should be developed for treatment of aggressive breast cancers, and possibly other types.  Targeting patients with an MCT4 inhibitor, or even simple antioxidants, may help treat high-risk patients, who otherwise may not respond positively to conventional treatment, the researchers suggest.

Paradigm Shift

But the work stems beyond triple negative breast cancer, challenging an 85-year-old theory about cancer growth and progression.

This paper is the missing clinical proof for the paradigm shift from the “old cancer theory” to the “new cancer theory,” known as the “Reverse Warburg Effect,” said Dr. Lisanti. The new theory being that aerobic glycolysis actually takes place in tumor associated fibroblasts, and not in cancer cells, as the old theory posits.

“The results by Witkiewicz et al. have prominent conceptual and therapeutic implications,” wrote Lorenzo Galluzzi, Ph.D., Oliver Kepp, Ph.D., and Guido Kroemer, M.D., Ph.D. of the French National Institute of Health and Medical Research and Institut Gustave Roussy, in an accompanying editorial. “First, they strengthen the notion that cancer is not a cell-autonomous disease, as they unravel that alterations of the tumor stroma may constitute clinically useful biomarkers”.

“Second, they provide deep insights into a metabolic crosstalk between tumor cells and their stroma that may be targeted by a new class of anticancer agents.”

Dr. Kroemer entitled his commentary “Reverse Warburg: Straight to Cancer” to emphasize that the connective tissue cells (fibroblasts) are directly “feeding” cancer cells, giving them a clear growth  and survival advantage.  New personalized therapies would cut off the “fuel supply” to cancer cells, halting tumor growth and metastasis.



Kimmel Cancer Center “All Hands Meeting”

The Kimmel Cancer Center held it’s quarterly “All Hands” meeting on March 14, 2012. Dr. Richard Pestell, Director of the Kimmel Cancer Center, delivered his quarterly “State of the Cancer Center” address. Awards were presented in 4 categories. The Administration/Wings Award was presented to Steven McKenzie, MD, PhD. The Basic Science Award was presented to John Pascal, PhD. The Nursing Award was presented to Deborah Turner, RN. The Clinical Award was presented to Edith Mitchell, MD.

Dr. Steven MCKenzie recieves Administrative/Wings Award from Dr. Richard Pestell

Dr. Steven MCKenzie recieves Administrative/Wings Award from Dr. Richard Pestell

Dr. John Pascal receives the Basic Science Award from Dr. Jeffrey Benovic

Dr. John Pascal receives the Basic Science Award from Dr. Jeffrey Benovic

Ms. Deborah Turner receives Nursing Award from Dr. Neal Flomenberg

Ms. Deborah Turner receives Nursing Award from Dr. Neal Flomenberg

Dr. Edith Mitchell receives Clinician Award from Dr. Neal Flomenberg

Dr. Edith Mitchell receives Clinician Award from Dr. Neal Flomenberg





Kimmel Cancer Center “All Hands Meeting”

The Kimmel Cancer Center held it’s quarterly “All Hands” meeting on December 23, 2011. Dr. Richard Pestell, Director of the Kimmel Cancer Center, delivered his quarterly “State of the Cancer Center” address. Awards were presented in six categories. The Administration Award was presented to Jeanine Voll. The Basic Science Award was presented to Agnieszka Witkiewicz, MD. The Nursing Award was presented to Maura Milligan, RN. The Clinical Award was presented to Nancy Lewis, MD. The “Discovery of the Year” Award was presented to Neal Flomnberg, MD and Dolores Grosso, RN, CRNP, DNP for their work in using haploindentical donors successfully in bone marrow transplants. The “Lifetime Achievement” Award was presented to Renato Baserga, MD.

Dr. Renato Baserga receives the "Lifetime Achievement" Award From Dr. Richard Pestell

Dr. Renato Baserga receives the "Lifetime Achievement" Award From Dr. Richard Pestell

Ms. Jeanine Voll receives Administration Award from Dr. Richard Davidson

Ms. Jeanine Voll receives Administration Award from Dr. Richard Davidson

Dr. Agnieszka Witkiewicz receives Basic Science Award from Dr. Richard Pestell



Dr. Nancy Lewis receives Clinical Award from Dr. Neal Flomenberg

Dr. Nancy Lewis receives Clinical Award from Dr. Neal Flomenberg

Dr. Neal Folmenberg and Dr. Dolores Grosso receive the "Discovery of the Year" Award from Dr. Richard Pestell

Dr. Neal Folmenberg and Dr. Dolores Grosso receive the "Discovery of the Year" Award from Dr. Richard Pestell




Rawls Palmer Progress in Medicine Award Presented to Dr. Scott A. Waldman

Scott A. Waldman, M.D., Ph.D., will receive the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Rawls–Palmer Progress in Medicine Award at the 2012 Annual Meeting on March 16.

Established in 1978 by Dr. W. B. Rawls, the award recognizes scientists who have implemented progressive research techniques and tools to improve patient care.

Scott Waldman, M.D., Ph.D.

ASCPT will present the award to Dr. Waldman prior to his lecture at the 113th Annual Meeting.

Dr. Waldman is the Samuel MV Hamilton Endowed Professor of Medicine, Vice President of Clinical and Translational Research, and Chair of the Department of Pharmacology and Experimental Therapeutics at Thomas Jefferson University. He is also Director of the Gastrointestinal Malignancies Program at the university’s Kimmel Cancer Center and Associate Dean of Clinical and Translational Sciences at Jefferson Medical College.

As a longtime volunteer leader of ASCPT, Dr. Waldman has participated on various committees and task forces, serving on the Board of Directors, as Society president, and as Editor in Chief of Clinical Pharmacology and Therapeutics since 2006.

Dr. Waldman has chaired numerous scientific review panels for the NIH and is on the editorial boards of Personalized Medicine, Expert Reviews in Clinical Pharmacology, and Regenerative Medicine, among others. He is the inaugural Deputy Editor of Clinical and Translational Science and the inaugural Senior Editor of Biomarkers in Medicine.

Dr. Waldman is a recognized clinician–investigator whose research ranges from molecular biology to cancer diagnostics and therapeutics. He received the 2010 ASCPT Henry Elliott Award and the 2011 Pharmaceutical Research and Manufacturers of America Foundation Award in Excellence for Clinical Pharmacology and Therapeutics.

About ASCPT

ASCPT is the leading forum for the discussion, development, and integration of clinical pharmacology in the drug development continuum—from discovery to safe and effective use. Headquartered in Alexandria, Virginia, ASCPT was established in 1900. Today, more than 2,100 ASCPT members are committed to advancing the science of human pharmacology and therapeutics worldwide.

*This release was reprinted with permission from ASCPT.



A New Battlefront: Symposium at Jefferson’s Kimmel Cancer Center to Tackle Geriatric Oncology

Approaches to treating elderly cancer patients are evolving as more of the population ages and the need for specialized care becomes more evident.

To address these issues and others, national thought leaders in geriatric oncology will gather at a unique symposium at the Kimmel Cancer Center at Jefferson (KCC) in Philadelphia on Friday, March 9, 2012, where they will present an overview of the latest advances in the understanding and treatment of cancer in older adults in an effort to impact patient care.

Outside of the annual American Society of Clinical Oncology (ASCO) meeting, this is the first regional symposium of its kind that would be addressing the needs of senior adults.

The all-day symposium, “The New Battlefront: Geriatric Oncology,” part of an annual series at the KCC, will be held at the Bluemle Life Sciences Building on Jefferson’s campus. Co-hosted by the KCC Cancer Network and Rothman Institute at Jefferson, it will provide comprehensive updates on basic science research and the latest updates on chemotherapy, surgery, and radiation in the care of senior adult patients.

Personalized Treatment

Geriatric patients make up 60 percent of new cancer diagnoses and 70 percent of all cancer deaths. And those numbers are expected to increase as the geriatric population doubles in size by 2030.

These patients also often must battle cancer in the context of multiple chronic conditions, decreased organ reserve, and all too often cognitive impairments.  What’s more, there’s currently a shortage of geriatric oncology physicians to treat them.

“Recognizing and addressing the particular co-morbidities, functional, and cognitive concerns, and identifying collaborations with other disciplines will help us better serve the population,” said Andrew E. Chapman, DO, FACP, who directs the KCC’s Senior Adult Oncology Center along with Christine A. Arenson, M.D, of the Department of Family and Community Medicine at Thomas Jefferson University Hospital.

A joint effort between the Departments of Medical Oncology and Family and Community Medicine, Division of Geriatrics, KCC’s Senior Adult Oncology Center provides a comprehensive assessment, usually during a single visit, to identify problems related to aging and cancer.   The program has medical oncologists, a geriatrician, a nurse navigator, a pharmacist specially trained in oncology and geriatrics, a registered dietician, and a social worker.

Facing this New Battlefront Together

During the symposium, the full spectrum of geriatric oncology care and research will be discussed by clinicians and researchers from top institutions, including Jan van Duersen, Ph.D., of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic in Rochester, Minn., and Arati V. Rao, M.D. of Duke University’s Division of Geriatrics.

The conference will provide an overview of the biology of cancer in aging, describe the state-of-the-art model of Shared Care for older cancer patients, and review critical issues of chemotherapy toxicity and optimal chemotherapy management.

Specific concerns for radiation therapy and surgery in the geriatric oncology patient will be also addressed. Finally, the latest advances in the management of hematologic and solid malignancies in the elderly will be shared.

Several of the talks also directly address patient and medication safety and improving communication among physicians, patients and other health care personnel.

Discussions will also focus on safe and effective use of chemotherapy and pharmacology safety issues, with talks by Arti Hurria M.D., director of the Cancer and Aging Research Program at the City of Hope National Medical Center and Stuart M. Lichtman, M.D., Professor of Medicine, 65+ Geriatric Clinical Program at Memorial Sloan-Kettering Cancer Center.

John A. Abraham, M.D., Chairman of the Division of Orthopedic Oncology at the Rothman Institute at Jefferson, will also speak about managing orthopedic issues in geriatric oncology patients.

“This symposium is an opportunity for players in the geriatric medicine and oncology, surgery and radiation fields to come together and highlight the innovative discoveries and best practices we believe will be important for the next generation of treatment and therapeutics in patients,” said Richard Pestell, M.D., Ph.D., director of the KCC and Professor and Chair of the Department of Cancer Biology at Jefferson Medical College of Thomas Jefferson University.

Other speakers include Rani P. Anné, M.D., Associate Professor of Radiation Oncology, Clinical Program Director at Jefferson Medical College at Thomas Jefferson University; William Dale, M.D., Ph.D., Chief of Section of Geriatrics and Palliative Medicine at University of Chicago Medical Center; Elizabeth M. Gore, M.D., Associate Director, Radiation Oncology at Medical College of Wisconsin; Supriya Gupta Mohile, M.D., M.S., Associate Professor of Medicine, Hematology/Oncology, University of Rochester Medical Center; Richard C. Wender; Alumni Professor and Chair, Family and Community Medicine, Jefferson Medical College; and Michael Zenilman, M.D., Professor of Surgery, Vice Chair and Director, National Capital Region, Johns Hopkins Medicine.

To register for the event, please visit http://www.kimmelcancercenter.org/symposium/



PCF Young Investigator Award Goes to Jefferson Researcher

Heather Montie, Ph.D., a post-doctoral research fellow in the Department of Biochemistry and Molecular Biology, has received a Prostate Cancer Foundation Young Investigator Award for her work with androgen receptor (AR) acetylation and its role in castration-resistant prostate cancer.

Young Investigator awards are designed to promote long-term careers in the field of prostate cancer by providing three year grants for transformational research focused on prostate cancer treatments to improve patient outcomes. Since 2007, PCF has invested more than $20 million in Young Investigator grants.

“PCF-supported young investigators have changed the scope of prostate cancer research, advancing treatment sciences and improving the lives of patients worldwide,” said Howard Soule, PhD, chief science officer and executive vice president of PCF. “It is with great pride and appreciation that PCF can now announce our young investigator program spans across six countries and 42 research institutes.”

Prostate cancer is driven by the male hormones, androgens which mediate their activity through the androgen receptor. Unfortunately most prostate cancerous tumors progressively become resistant to the preferred treatment modality, androgen deprivation therapy. One of the mechanisms proposed to enhance the activity of androgen receptors in castration-resistant prostate cancer, even in the absence of androgens, is the addition of a small chemical group/moiety to the AR protein. This modification of AR is termed ‘acetylation’ and is proposed to convert the protein to a ‘super AR.’

However, there is currently no experimental data to show that AR acetylation directly enhances AR-dependent prostate cancer cell viability.

Dr. Montie proposes to evaluate the role of AR acetylation in the enhanced AR functional activity central to CRPC. She will study the precise mechanisms by which this modification of AR enhances its cancer-promoting activity. Dr. Montie will also validate the potential of AR acetylation as a therapeutic target for castrate-resistant prostate cancer.

A total of 15 competitive research grants have been awarded to-date in 2012, bringing the total of young investigators awarded to 89.

Each Young Investigator recipient is awarded $225,000 over a three-year period.

Dr. Montie received the 2012 John A. Moran PCF Young Investigator Award. 

Visit here for more on the Young Investigator awards.



Dr. Renato V. Iozzo receives an honorary degree from Semmelweis University in Budapest, Hungary

Congratulations to Renato V. Iozzo, M.D., a Professor of Pathology and Cell Biology, and Professor of Biochemistry & Molecular Biology, Thomas Jefferson University, for receiving an honorary degree (Doctor Honoris Causa) from Semmelweis University in Budapest, Hungary.

Dr. Iozzo received this award in November 2011 in recognition for his contributions to the field of Matrix Biology, Cancer and Angiogenesis.

His research focuses on the biology of proteoglycans and their roles in cancer and angiogenesis, and has published over 275 peer-reviewed articles, numerous reviews and edited two books on proteoglycans.

After receiving an M.D. degree summa cum laude from the University of Florence, Italy, Dr. Iozzo moved to the Department of Pathology at the University of Washington, where he completed a five-year Residency/Fellowship. Following a six-year faculty appointment at the University of Pennsylvania, he was promoted to Associate Professor and then moved the same year to Thomas Jefferson University as Full Professor with tenure.

Founded in 1769 by Maria Theresa the Empress of Austria-Hungary, Semmelweis University is one of the oldest universities and medical schools in Europe.



Stronger Intestinal Barrier May Prevent Cancer in the Rest of the Body, New Study Suggests

Scott Waldman, M.D., Ph.D., chair of the Department of Pharmacology and Experimental Therapeutics at Jefferson and director of the Gastrointestinal Cancer Program at Jefferson’s Kimmel Cancer Center

A leaky gut may be the root of some cancers forming in the rest of the body, a new study published online Feb. 21 in PLoS ONE by Thomas Jefferson University researchers suggests.

It appears that the hormone receptor guanylyl cyclase C (GC-C)—a previously identified tumor suppressor that exists in the intestinal tract—plays a key role in strengthening the body’s intestinal barrier, which helps separate the gut world from the rest of the body, and possibly keeps cancer at bay. Without the receptor, that barrier weakens.

A team led by Scott Waldman, M.D., Ph.D., chair of the Department of Pharmacology and Experimental Therapeutics at Jefferson and director of the Gastrointestinal Cancer Program at Jefferson’s Kimmel Cancer Center, discovered in a pre-clinical study that silencing GC-C in mice compromised the integrity of the intestinal barrier.  It allowed inflammation to occur and cancer-causing agents to seep out into the body, damaging DNA and forming cancer outside the intestine, including in the liver, lung and lymph nodes.

Conversely, stimulating GC-C in intestines in mice strengthened the intestinal barrier opposing these pathological changes.

A weakened intestinal barrier has been linked to many diseases, like inflammatory bowel disease, asthma and food allergies, but this study provides fresh evidence that GC-C plays a role in the integrity of the intestine.  Strengthening it, the team says, could potentially protect people against inflammation and cancer in the rest of the body.

“If the intestinal barrier breaks down, it becomes a portal for stuff in the outside world to leak into the inside world,” said Dr. Waldman. “When these worlds collide, it can cause many diseases, like inflammation and cancer.”

The role of GC-C outside the gut has remained largely elusive. Dr. Waldman and his team have previously shown its role as a tumor suppressor and biomarker that reveals occult metastases in lymph nodes. They’ve used to it better predict cancer risk, and have even shown a possible correlation with obesity.

Reporting in the Journal of Clinical Investigation, Dr. Waldman colleagues found that silencing GC-C affected appetite in mice, disrupting satiation and inducing obesity. Conversely, mice who expressed the hormone receptor knew when to call it quits at mealtime.

However, its role in intestinal barrier integrity, inflammation, and cancer outside the intestine is new territory in the field.

A new drug containing GC-C is now on the verge of hitting the market, but its intended prescribed purpose is to treat constipation.

This study helps lays the groundwork, Dr. Waldman said, for future pre-clinical and clinical studies investigating GC-C’s abilities beyond those treatments in humans, including prevention and treatment of inflammatory bowel disease and cancer.

“We’ve shown that when you pull away GC-C in animals, you disrupt the intestinal barrier, putting them at risk for getting inflammatory bowel disease and cancer.  And when you treat them with hormones that activate GC-C it helps strengthen the integrity of the intestinal barrier,” Dr. Waldman said.  “Now, if you want to prevent inflammation or cancer in humans, then we need to start thinking about feeding people hormones that activate GC-C to tighten up the barrier.”



Jefferson’s Kimmel Cancer Center Establishes Center to Eliminate Cancer Disparities

Dr. Edith Mitchell, director of newly-established Center to Eliminate Cancer Disparities, and Robin Evans, a patient.

PHILADELPHIA—In an effort to reduce and eventually eliminate cancer disparities among adults in the Philadelphia region, the Kimmel Cancer Center at Jefferson has established the Center to Eliminate Cancer Disparities.

Edith P. Mitchell, M.D., FACP, a medical oncologist at Thomas Jefferson University Hospital and Clinical Professor of Medicine and Medical Oncology in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, will serve as its Director.

Despite the decline in cancer incidence and mortality rates in the United States, disparities in cancer burdens continue to exist among certain population groups and the gap continues to widen.  The Philadelphia region in particular has a disproportionately high number of residents suffering from cancers, many of which are preventable and treatable.

Such disparities include differences in incidence, prevalence, mortality and burden of cancer and related adverse health conditions. Disparate population groups may be characterized by gender, age, race and ethnicity, income, social class, disability, geographic location or sexual orientation.

“I have dedicated my career to the treatment of cancer patients and have had the opportunity to experience, as a physician and as a researcher, the significance cancer disparities can have on the outcome of a patient’s treatment,” said Dr. Mitchell. “The first step in the elimination of these disparities is to raise awareness through public and professional education about what resources are available to groups in their fight against cancer.”

The Center aims to accomplish its mission through the facilitation of disparities-focused research, researcher and clinician education, training and teaching, and increased patient access to quality supportive services, such as palliative care, cancer screening and prevention, and survivorship programs.

Dr. Mitchell and her fellow clinicians and researchers at Jefferson are dedicated to the ongoing study of cancer and other health disparities among patients of diverse ethnic and socioeconomic backgrounds. They have created strategic priorities for eliminating such disparities through innovative research, education and training, advocacy, community outreach, and quality medical care.

The need for research into cancer, and other health care disparities, has become increasingly evident in recent years as doctors and scientists learn more about how slight variations in genetic makeup can have drastic effects on the way cancer invades an individual’s body.  Knowing that these disparities exist can improve how screening processes are established and help doctors understand which treatments will and will not be effective.

Dr. Mitchell has spent her medical career helping individuals in medically underserved areas to realize that simple changes in lifestyle can have a dramatic impact on cancer care. Through her work, Dr. Mitchell has demonstrated the importance of community service and outreach especially to those individuals who may not have the means to seek out more conventional medical advice.

She holds board certifications in both Internal Medicine and Medical Oncology and is a Fellow in the American College of Physicians. She has also served as the Program Leader in gastrointestinal oncology for more than 15 years and has a focused research effort in aggressive breast cancers.

“We want all researchers and clinicians to be aware of the disparities that exist in cancer diagnoses among diverse ethnic groups so that they can incorporate these important factors into their research efforts and clinical practice,” said Dr. Mitchell.

“The Center will also provide patients with contact information for cancer advocacy and support groups both locally and nationally that serve the needs of their demographic background. We are proud to host and sponsor several annual events where patients can come together to share their stories and plan for a future free of cancer disparities,” she said.



Taxpayers Give Back for Cancer: Jefferson Researcher Awarded ‘Refunds for Research’ Grant

Takemi Tanaka, Ph.D., of Thomas Jefferson University’s School of Pharmacy and the Kimmel Cancer Center

Takemi Tanaka, Ph.D., of Thomas Jefferson University’s School of Pharmacy and the Kimmel Cancer Center, received a $50,000 grant toward her breast cancer research, as part of the Pennsylvania Breast Cancer Coalition’s (PBCC) “Refunds for Breast and Cervical Cancer Research” initiative.

The PBCC’s grants are made possible through contributions from state taxpayers who choose to contribute all or part of their state income tax refund to the program.

Dr. Tanaka’s research focuses on breast cancer metastasis. When cancer metastasizes, cancer cells enter the distal organs through the blood vessels. Dr. Tanaka envisions those vessels as a gateway for the cells and wants to close it as tight as possible to prevent the cancer from spreading further.

Her team developed a new drug called ESTA to block the entry of breast cancer cells into the tissue.  Early data show that mice treated with the drug had 60 percent less metastases without toxicity.

From the left: Ashiwel Undieh, Chair of Pharmaceutical Sciences, Pat Halpin-Murphy, founder of PBCC, Dr. Tanaka, and Rebecca Finley, Dean of the Jefferson School of Pharmacy

“I would like to express my sincere gratitude to the tax payers for their generous support for my breast cancer research to help eradicate this deadly disease,” Dr. Tanaka said. “We believe that success with our strategy may transform current breast cancer therapy and move us one step closer to a cure.”

Dr. Tanaka is one of three researchers who received funding through PBCC’s Breast and Cervical Cancer Research initiative. The other recipients are from the University of Pennsylvania and Penn State Hershey Cancer Institute.

“We’re extremely proud of Dr. Tanaka’s recognition by the Pa. Breast Cancer Coalition and thankful for the people in Pennsylvania who donated to help support these grants, as well as the PBCC for their efforts to raise awareness about breast cancer,” said Rebecca Finley, PharmD, M.S., Dean of Jefferson’s School of Pharmacy. “Dr. Tanaka’s work with this promising new drug will only help us better understand and potentially better treat this important health issue in women.”

The PBCC kicked off its annual Refunds for Breast and Cervical Cancer Research campaign to fund the cancer researchers on Monday, Feb. 13 at City Hall with Councilmen Dennis O’Brien.

Since 1997, more than $2.8 million has been donated to the Refunds for Research campaign and 71 grants have been awarded to Pennsylvania researchers looking for the cause of and cure for these common cancers in women.



Curry spice component may help slow prostate tumor growth

Karen Knudsen, PhD, a Professor of Cancer Biology, Urology and Radiation Oncology

Curcumin, an active component of the Indian curry spice turmeric, may help slow down tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy (ADT), a study from researchers at Jefferson’s Kimmel Cancer Center suggests.

Reporting in a recent issue of Cancer Research, Karen Knudsen, Ph.D., a Professor of Cancer Biology, Urology and Radiation Oncology at Thomas Jefferson University, Supriya Shah, a Jefferson graduate student in Cancer Biology, and colleagues observed in a pre-clinical study that curcumin suppresses two known nuclear receptor activators, p300 and CBP (or CREB1-binding protein), which have been shown to work against ADT.

ADT aims to inhibit the androgen receptor—an important male hormone in the development and progression of prostate cancer—in patients. But a major mechanism of therapeutic failure and progression to advanced disease is inappropriate reactivation of this receptor. Sophisticated tumor cells, with the help of p300 and CBP, sometimes bypass the therapy.

Thus, development of novel targets that act in concert with the therapy would be of benefit to patients with castration-resistant prostate cancer.

For the study, prostate cancer cells were subjected to hormone deprivation in the presence and absence of curcumin with “physiologically attainable’ doses. (Previous studies, which found similar results, included doses that were not realistic.)

Curcumin augments the results of ADT, and reduced cell number compared to ADT alone, the researchers found. Moreover, the spice was found to be a potent inhibitor of both cell cycle and survival in prostate cancer cells.

To help support their findings, the researchers also investigated curcumin in mice, which were castrated to mimic ADT. They were randomized into two cohorts: curcumin and control. Tumor growth and mass were significantly reduced in the mice with curcumin, the researchers report.

These data demonstrate for the first time that curcumin not only hampers the transition of ADT-sensitive disease to castration-resistance, but is also effective in blocking the growth of established castrate-resistant prostate tumors.

“This study sets the stage for further development of curcumin as a novel agent to target androgen receptor signaling,” said Dr. Knudsen. “It also has implications beyond prostate cancer since p300 and CBP are important in other malignancies, like breast cancer. In tumors where these play an important function, curcumin may prove to be a promising therapeutic agent.”



2011 Men’s Event Benefiting Prostate Cancer Research and patient care at Jefferson’s Kimmel Cancer Center

On Tuesday, November, 17th 2011, the Kimmel Cancer Center at Jefferson held the Third Annual Men’s Event benefiting prostate cancer research and patient care at the Prime Rib Restaurant in Philadelphia. The Men’s Event was emceed by Philadelphia Eagles Longsnapper, motivational speaker and magician, Jon Dorenbos.

Receiving the Symbol of Courage was John Beuhler, prostate cancer survivor and grateful patient of Thomas Jefferson University Hospital.  The Symbol of Caring was presented to Kenneth Boone, board member of Thomas Jefferson University Hospital.

Special guests included Amber-Joi Watkins, Miss USA Pennsylvania and Julianna White, Miss USA New Jersey. Guests enjoyed a dinner, silent and live auction, and casino.

The Lead Sponsor was Bill Frankel of Frankel Enterprises. Kimmel Cancer Center would also like to thank the following sponsors:

Sponsor Company / Group Silent Auction/ Company
AP Executive Management Algar Ferrari of Philadelphia
Barry Bressler, Esq. and Betty Gross Eisenberg American Male Salon
BlankRome Annie-Prue
Boone Properties, LLC Atlantic City Country Club
Chamber Orchestra of Philadelphia Bistrot La Minette
Charles Pike Construction Blackfish Restaurant
Citi Blue Horizons Dive Center
Commonwealth Agency, Inc. Boyds
Dann, Dorfman, Herrell & Skillman, PC Chadds Ford
David Yurman Jewelers Chelsea Hotel
DBA The Wyndon Group City of Philadelphia Mural Arts Program
Deitz & Watson Cooperage Wine and Whiskey Bar
Department of Medical Oncology Cross Winds Flight School
Dilworth Paxson D’Angelo’s Restaurant
Drs. Gomella and Family David Yurman
Electronic Ink Dock’s Oyster House/Knife & Fork Atlantic City
Firstrust Drexel University Men’s Basketball
Frankel Enterprises Electronic Ink
Heffler, Radetich & Saitta Fencing Academy of Philadelphia
Hi Fi House Fogo de Chao
Koegle Family Four Seasons Hotel
M&T Bank Kenneth Freeling and Sue Cimbricz
McCullough Models From My Harp – Cheryl Kripke Cohen
PREIT Gomella Family
Rodin IFC Henry A. Davidsen
Stradley Ronon Hidden Creek Golf Club
TD Bank Holt’s Cigar Company
Unique Products Hortman Aviation Services
US Bank J. Lohr
Jacques Ferber
Joseph Anthony Spa
Jump NEA
Kramer Portraits New York
La Prairie
Lacoste
Lacroix
Le Castagne
Lehigh Valley
Limoncello
Lord & Taylor, Bala Cywyd
Lucky Strikes
Manito Equestrian Center
May’s Landing Golf Club
McCullough’s Emerald Golf Links
Merion Country Club
Mid-Atlantic Restaurant
Milkboy
Monsu
Nangellini
Nicole Miller
Pennsylvania Paragliding
Philadelphia Sports Club
Piper Memorial Airport
Quaker State Light Sport Flight Academy, LLC.
Ralph Lauren
Ristorante Panorama
Saks Fifth Avenue, Bala Cynwyd
Salon Ziza
Segway Tours
Skirmish
St. Joe’s University Men’s Basketball
Target Masters Gold Membership
The Chamber Orchestra of Philadelphia
The Little Tuna
The Prime Rib
The Union Trust
The Vesper Club
Thomas J Duffy, Esq.
Tiffany’s
Time Restaurant
Twin Pines Stables and Unique Industries
Twisted Tail
Ultimate Shave
Union League of Philadelphia
Villanova University Men’s Basketball
Villanova University Football
Victory Brewing Co.
Vintage Wine Bar
West Avenue Grille
Whitewater Challengers




The Third Annual Men’s Event would not have been possible without the tremendous work and support of our Committee members:

Barry Bressler Rose Cunningham
Robert DeBolt Marc Feller
Marc Franzoni Peter Gistelinck
Bruce Goldman Tricia Gomella
Niels Haun Mark Juliano
Erik Knudsen Bryan Koegel
John LeVine Bill McCullough
Meredith Seigle Roger Vander Klock
Thomas Walls



Special thanks to Gerard Tomko Wedding Photography for donating his services in-kind.



Jefferson appoints Administrator, Radiation Oncology

Thomas Jefferson University Hospital has selected Alex Khariton to become its Administrator for the Department of Radiation Oncology.

Previously, Mr. Khariton had been the Administrative Director for the Department of Radiation Oncology at Cooper University Hospital in Camden, N.J., for the past eight years.

“I”m looking forward to working for an  NCI-designated cancer center that provides excellent clinical car, partakes in innovative research, and has a well-respected medical school,” says Alex.

Alex is also Co-Chair of the Reimbursement and Economic committee for the SROA (Society of Radiation Oncology Administrators) and a member of  the American Society for Therapeutic Radiology and Oncology (ASTRO).

The new hire announcement was featured online in the Philadelphia Business Journal’s “People on the Move” section:

http://www.bizjournals.com/philadelphia/potmsearch/detail/submission/511141